Modification of blood pressure in postmenopausal women: role of hormone replacement therapy
| Autor: | Marianna Cannoletta, Angelo Cagnacci |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Ambulatory blood pressure hypertension medicine.drug_class medicine.medical_treatment menopause Review Internal medicine Maternity and Midwifery estrogen Medicine business.industry blood pressure hormone replacement therapy progestin Obstetrics and Gynecology Drospirenone Hormone replacement therapy (menopause) medicine.disease Menopause Blood pressure Endocrinology Oncology Estrogen Hormone therapy business Progestin hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | International Journal of Women's Health |
| Popis: | The rate of hypertension increases after menopause. Whether estrogen and progesterone deficiency associated with menopause play a role in determining a worst blood pressure (BP) control is still controversial. Also, studies dealing with the administration of estrogens or hormone therapy (HT) have reported conflicting evidence. In general it seems that, despite some negative data on subgroups of later postmenopausal women obtained with oral estrogens, in particular conjugated equine estrogens (CEE), most of the data indicate neutral or beneficial effects of estrogen or HT administration on BP control of both normotensive and hypertensive women. Data obtained with ambulatory BP monitoring and with transdermal estrogens are more convincing and concordant in defining positive effect on BP control of both normotensive and hypertensive postmenopausal women. Overall progestin adjunct does not hamper the effect of estrogens. Among progestins, drospirenone, a spironolactone-derived molecule, appears to be the molecule with the best antihypertensive properties. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|